K. Andreatta

发表

High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I

K. White, P. Sax, J. Gallant, 2022, AIDS.

HIV-2 Antiviral Potency and Selection of Drug Resistance Mutations by the Integrase Strand Transfer Inhibitor Elvitegravir and NRTIs Emtricitabine and Tenofovir In Vitro

K. White, M. Miller, K. Andreatta, 2013, Journal of acquired immune deficiency syndromes.

Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI

J. van Lunzen, A. Lazzarin, J. Arribas, 2017, HIV clinical trials.

Reduced Viral Fitness and Lack of Cross-Class Resistance with Integrase Strand Transfer Inhibitor and Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations

K. White, D. Goodman, M. Miller, 2015, Antimicrobial Agents and Chemotherapy.

Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI

D. Ward, A. Antinori, J. Flamm, 2017, HIV clinical trials.

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

K. White, M. Tsiang, Gregg S. Jones, 2012, Antiviral research.

Baseline Antiretroviral Resistance Mutations and Treatment-Emergent Resistance in HIV-1 RNA-Suppressed Patients Switching to EVG/COBI/FTC/TDF or Continuing on Their PI-, NNRTI-, or RAL-Based Regimen

K. White, H. Cao, M. Abram, 2015, Journal of acquired immune deficiency syndromes.

Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study*

K. White, F. Palella, Y. Lie, 2016, HIV clinical trials.

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

K. White, Xiaowu Chen, E. Svarovskaia, 2013, Antimicrobial Agents and Chemotherapy.

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

J. Rockstroh, E. Daar, J. Molina, 2018, The lancet. HIV.

Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate in HIV-1-infected Adolescents Failing Antiretroviral Therapy: The Final Results of Study GS-US-104–0321

J. Pinto, E. Quirk, M. Z. de Aquino, 2015, The Pediatric infectious disease journal.

Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials

K. White, Ross Martin, Hal Martin, 2021, Journal of acquired immune deficiency syndromes.

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study

M. Saag, M. Ramgopal, D. Brainard, 2021, Journal of acquired immune deficiency syndromes.

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-Existing NRTI Resistance.

K. White, Ross Martin, Hal Martin, 2020, Journal of acquired immune deficiency syndromes.

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

K. White, Ross Martin, E. Quirk, 2019, The Journal of antimicrobial chemotherapy.

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

D. Podzamczer, H. Stellbrink, D. Ward, 2018, The lancet. HIV.

Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions

K. White, M. Miller, K. Andreatta, 2015, Antimicrobial Agents and Chemotherapy.

HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate.

K. White, A. Thielen, Ross Martin, 2018, Journal of acquired immune deficiency syndromes.

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

K. White, M. Tsiang, Gregg S. Jones, 2012, Antiviral research.

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

D. Podzamczer, H. Stellbrink, D. Ward, 2018, The lancet. HIV.